Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of JW0202/C2202 vs C2205/JW0201 in Healthy Volunteers
NCT06361277Phase 1Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Nov 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of gemigliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by JW Pharmaceutical Corporation. Primary endpoints: Area Under the Curve to the last measurable concentration and Maximum Plasma Concentration. Started Nov 2023; status: completed.
02
Drugs
gemigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06361277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06361277.